Adjuvant CDK 4/6 Inhibitors for High-Risk HR+/HER2– Early Breast Cancer: Toxicity Management and Real-World Data

Video content above is prompted by the following:

• What specific patient characteristics influence your choice between abemaciclib and ribociclib?
• In which scenarios would you preferentially choose abemaciclib over ribociclib? Ribociclib over abemaciclib?
• Could you discuss your approach to toxicity management with adjuvant CDK4/6 inhibitors?
• How do the different safety profiles of abemaciclib and ribociclib impact your patient selection? How do you weigh clinical considerations and comorbidities in your selection considerations?
• What strategies have you found most effective for maintaining dose intensity while managing adverse effects?
• How has real-world experience with adjuvant CDK4/6 inhibitors matched up with clinical trial data?
• What have been your key learnings about patient selection and management?
• How do you handle patients who struggle with adherence or toxicity in the first few months?